HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole.

AbstractPURPOSE:
Endocrine agents, such as letrozole, are established in the treatment of hormone-dependent breast cancer. However, response rates are only 50% to 70% in the neoadjuvant setting and lower in advanced disease. Thus there is a need to identify novel markers predicting for response and to understand molecular mechanisms of resistance.
PATIENTS AND METHODS:
Sequential tumor biopsies were taken before and after 10 to 14 days of neoadjuvant treatment with letrozole in patients with estrogen receptor-rich breast cancer. Expression profiles on high-density microarray chips were then related to clinical responses as assessed from tumor volume measurements after 3 months of treatment.
RESULTS:
Of 52 patients, 37 (71%) were classified as having a clinical response to letrozole and 15 being clinically resistant. Bioinformatic analysis identified 205 covariables (69 baseline expression, 45 day 14 expression, and 91 change in expression with treatment) which differentiated between clinical responders and nonresponders. Hierarchical clustering using the variables separated responders and nonresponders into two distinct groups. Ontological assessment indicated that discriminating genes were enriched toward cellular biosynthetic processes. In particular, functional gene assessment showed ribosomal protein probes to have higher baseline expression in tumors responsive to letrozole and increased expression with treatment in nonresponding cases.
CONCLUSION:
To our knowledge, this is the first study to describe genetic covariables and molecular processes discriminating between tumors clinically responsive and resistant to an aromatase inhibitor. The understanding of such molecular phenotypes will be important in optimizing the clinical use of aromatase inhibitors, both in terms of identifying responsive breast cancers and developing new agents to target resistance pathways.
AuthorsWilliam R Miller, Alexey Larionov, Lorna Renshaw, Thomas J Anderson, John R Walker, Andreas Krause, Tobias Sing, Dean B Evans, J Michael Dixon
JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology (J Clin Oncol) Vol. 27 Issue 9 Pg. 1382-7 (Mar 20 2009) ISSN: 1527-7755 [Electronic] United States
PMID19224856 (Publication Type: Journal Article)
Chemical References
  • Antineoplastic Agents
  • Aromatase Inhibitors
  • Nitriles
  • RNA, Neoplasm
  • Receptors, Estrogen
  • Triazoles
  • letrozole
Topics
  • Antineoplastic Agents (therapeutic use)
  • Aromatase Inhibitors (therapeutic use)
  • Biopsy
  • Breast Neoplasms (drug therapy, genetics, metabolism, pathology)
  • Drug Resistance, Neoplasm
  • Female
  • Gene Expression Profiling
  • Humans
  • Neoadjuvant Therapy
  • Neoplasms, Hormone-Dependent (drug therapy, genetics, metabolism, pathology)
  • Nitriles (therapeutic use)
  • Oligonucleotide Array Sequence Analysis
  • Postmenopause
  • Prospective Studies
  • RNA, Neoplasm (genetics)
  • Receptors, Estrogen (biosynthesis)
  • Triazoles (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: